Metformin, a widely-used AMPK activator in clinics for type 2 diabetes, was reported to ameliorate fatty liver by reducing mRNA and nuclear protein of SREBP1 [45]. This evidence concerns the gene SREBF1 and type 2 diabetes mellitus.